Celgene reports 4Q17 earns, expresses interest in M&A

Celgene Corp. (NASDAQ:CELG) reported fourth quarter earnings Thursday, including EPS that topped the Street's estimates, driven by U.S. sales of cancer drug Revlimid lenalidomide. On the heels of two acquisition deals this month, Celgene also said it is open to more M&A, if the science warrants.

Compared to 4Q16, Celgene said Revlimid sales grew 24% to $1.5 billion in 4Q17, "fueled by continued gains in duration and market share." The company expects to submit an sNDA this quarter for the drug in first-line multiple myeloma (MM)...